{
    "root": "2cd5dbfd-2432-4cea-bee2-6b710b5d28a2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Letrozole"
    },
    "value": "20250328",
    "ingredients": [
        {
            "name": "LETROZOLE",
            "code": "7LKK855W8I"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 101",
            "code": "7T9FYH5QMK"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "Letrozole is an aromatase inhibitor indicated for: Adjuvant     treatment of postmenopausal women with hormone receptor positive early breast cancer.     ( 1.1 ) Extended adjuvant treatment of postmenopausal women     with early breast cancer who have received prior standard adjuvant tamoxifen therapy.     ( 1.2 ) First and second-line treatment of postmenopausal     women with hormone receptor positive or unknown advanced breast cancer. ( 1.3 )",
    "contraindications": "Letrozole tablets are taken orally without regard to meals ( 2 ): Recommended dose: 2.5 mg once daily. ( 2.1 ) Patients with cirrhosis or severe hepatic impairment: 2.5 mg every other day. ( 2.5 , 5.3 )",
    "warningsAndPrecautions": "Letrozole Tablets USP 2.5 mg are dark yellow, film-coated, round, slightly biconvex, with beveled edges debossed with ‘L2.5’ on one side and plain on other side. They are supplied as follows:\n                  \n                  Bottles of 30        NDC 59651-180-30\n                  Bottles of 90        NDC 59651-180-90\n                  \n                  Store at 20o to 25oC (68o to 77oF) [see USP Controlled Room Temperature].",
    "adverseReactions": "Pregnancy: Letrozole can  cause fetal harm [see Use in Specific Populations (8.1)].\n                     \n                     Known hypersensitivity to the active substance, or to any of the excipients [see Adverse Reactions (6)]."
}